Whole genome sequencing

Last updated
Electropherograms are commonly used to sequence portions of genomes. Chromatogram.jpg
Electropherograms are commonly used to sequence portions of genomes.
Schematic karyogram of a human, showing an overview of the human genome, with 22 homologous chromosomes, both the female (XX) and male (XY) versions of the sex chromosome (bottom right), as well as the mitochondrial genome (to scale at bottom left) Human karyotype with bands and sub-bands.png
Schematic karyogram of a human, showing an overview of the human genome, with 22 homologous chromosomes, both the female (XX) and male (XY) versions of the sex chromosome (bottom right), as well as the mitochondrial genome (to scale at bottom left)

Whole genome sequencing (WGS) is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time. [2] This entails sequencing all of an organism's chromosomal DNA as well as DNA contained in the mitochondria and, for plants, in the chloroplast.

Contents

Whole genome sequencing has largely been used as a research tool, but was being introduced to clinics in 2014. [3] [4] [5] In the future of personalized medicine, whole genome sequence data may be an important tool to guide therapeutic intervention. [6] The tool of gene sequencing at SNP level is also used to pinpoint functional variants from association studies and improve the knowledge available to researchers interested in evolutionary biology, and hence may lay the foundation for predicting disease susceptibility and drug response.

Whole genome sequencing should not be confused with DNA profiling, which only determines the likelihood that genetic material came from a particular individual or group, and does not contain additional information on genetic relationships, origin or susceptibility to specific diseases. [7] In addition, whole genome sequencing should not be confused with methods that sequence specific subsets of the genome – such methods include whole exome sequencing (1–2% of the genome) or SNP genotyping (< 0.1% of the genome).

History

The first bacterial whole genome to be sequenced was of the bacterium Haemophilus influenzae. Haemophilus influenzae 01.jpg
The first bacterial whole genome to be sequenced was of the bacterium Haemophilus influenzae .
The worm Caenorhabditis elegans was the first animal to have its whole genome sequenced. C. elegans.jpg
The worm Caenorhabditis elegans was the first animal to have its whole genome sequenced.
Drosophila melanogaster's whole genome was sequenced in 2000. Drosophila melanogaster - front (aka).jpg
Drosophila melanogaster 's whole genome was sequenced in 2000.
Arabidopsis thaliana was the first plant genome sequenced. Arabidopsis thaliana inflorescencias.jpg
Arabidopsis thaliana was the first plant genome sequenced.
The genome of the lab mouse Mus musculus was published in 2002. 54986main mouse med.jpg
The genome of the lab mouse Mus musculus was published in 2002.
It took 10 years and 50 scientists spanning the globe to sequence the genome of Elaeis guineensis (oil palm). This genome was particularly difficult to sequence because it had many repeated sequences which are difficult to organise. Elaeis guineensis MS 3467.jpg
It took 10 years and 50 scientists spanning the globe to sequence the genome of Elaeis guineensis (oil palm). This genome was particularly difficult to sequence because it had many repeated sequences which are difficult to organise.

The DNA sequencing methods used in the 1970s and 1980s were manual; for example, Maxam–Gilbert sequencing and Sanger sequencing. Several whole bacteriophage and animal viral genomes were sequenced by these techniques, but the shift to more rapid, automated sequencing methods in the 1990s facilitated the sequencing of the larger bacterial and eukaryotic genomes. [9]

The first virus to have its complete genome sequenced was the Bacteriophage MS2 by 1976. [10] In 1992, yeast chromosome III was the first chromosome of any organism to be fully sequenced. [11] The first organism whose entire genome was fully sequenced was Haemophilus influenzae in 1995. [12] After it, the genomes of other bacteria and some archaea were first sequenced, largely due to their small genome size. H. influenzae has a genome of 1,830,140 base pairs of DNA. [12] In contrast, eukaryotes, both unicellular and multicellular such as Amoeba dubia and humans ( Homo sapiens ) respectively, have much larger genomes (see C-value paradox). [13] Amoeba dubia has a genome of 700 billion nucleotide pairs spread across thousands of chromosomes. [14] Humans contain fewer nucleotide pairs (about 3.2 billion in each germ cell – note the exact size of the human genome is still being revised) than A. dubia, however, their genome size far outweighs the genome size of individual bacteria. [15]

The first bacterial and archaeal genomes, including that of H. influenzae, were sequenced by Shotgun sequencing. [12] In 1996, the first eukaryotic genome ( Saccharomyces cerevisiae ) was sequenced. S. cerevisiae, a model organism in biology has a genome of only around 12 million nucleotide pairs, [16] and was the first unicellular eukaryote to have its whole genome sequenced. The first multicellular eukaryote, and animal, to have its whole genome sequenced was the nematode worm: Caenorhabditis elegans in 1998. [17] Eukaryotic genomes are sequenced by several methods including Shotgun sequencing of short DNA fragments and sequencing of larger DNA clones from DNA libraries such as bacterial artificial chromosomes (BACs) and yeast artificial chromosomes (YACs). [18]

In 1999, the entire DNA sequence of human chromosome 22, the second shortest human autosome, was published. [19] By the year 2000, the second animal and second invertebrate (yet first insect) genome was sequenced – that of the fruit fly Drosophila melanogaster – a popular choice of model organism in experimental research. [20] The first plant genome – that of the model organism Arabidopsis thaliana – was also fully sequenced by 2000. [21] By 2001, a draft of the entire human genome sequence was published. [22] The genome of the laboratory mouse Mus musculus was completed in 2002. [23]

In 2004, the Human Genome Project published an incomplete version of the human genome. [24] In 2008, a group from Leiden, the Netherlands, reported the sequencing of the first female human genome (Marjolein Kriek).

Currently thousands of genomes have been wholly or partially sequenced.

Experimental details

Cells used for sequencing

Almost any biological sample containing a full copy of the DNA—even a very small amount of DNA or ancient DNA—can provide the genetic material necessary for full genome sequencing. Such samples may include saliva, epithelial cells, bone marrow, hair (as long as the hair contains a hair follicle), seeds, plant leaves, or anything else that has DNA-containing cells.

The genome sequence of a single cell selected from a mixed population of cells can be determined using techniques of single cell genome sequencing. This has important advantages in environmental microbiology in cases where a single cell of a particular microorganism species can be isolated from a mixed population by microscopy on the basis of its morphological or other distinguishing characteristics. In such cases the normally necessary steps of isolation and growth of the organism in culture may be omitted, thus allowing the sequencing of a much greater spectrum of organism genomes. [25]

Single cell genome sequencing is being tested as a method of preimplantation genetic diagnosis, wherein a cell from the embryo created by in vitro fertilization is taken and analyzed before embryo transfer into the uterus. [26] After implantation, cell-free fetal DNA can be taken by simple venipuncture from the mother and used for whole genome sequencing of the fetus. [27]

Early techniques

An ABI PRISM 3100 genetic analyzer. Such capillary sequencers automated the early efforts of sequencing genomes. ABI PRISM 3100 Genetic Analyzer 3.jpg
An ABI PRISM 3100 genetic analyzer. Such capillary sequencers automated the early efforts of sequencing genomes.

Sequencing of nearly an entire human genome was first accomplished in 2000 partly through the use of shotgun sequencing technology. While full genome shotgun sequencing for small (4000–7000 base pair) genomes was already in use in 1979, [28] broader application benefited from pairwise end sequencing, known colloquially as double-barrel shotgun sequencing. As sequencing projects began to take on longer and more complicated genomes, multiple groups began to realize that useful information could be obtained by sequencing both ends of a fragment of DNA. Although sequencing both ends of the same fragment and keeping track of the paired data was more cumbersome than sequencing a single end of two distinct fragments, the knowledge that the two sequences were oriented in opposite directions and were about the length of a fragment apart from each other was valuable in reconstructing the sequence of the original target fragment.

The first published description of the use of paired ends was in 1990 as part of the sequencing of the human HPRT locus, [29] although the use of paired ends was limited to closing gaps after the application of a traditional shotgun sequencing approach. The first theoretical description of a pure pairwise end sequencing strategy, assuming fragments of constant length, was in 1991. [30] In 1995, the innovation of using fragments of varying sizes was introduced, [31] and demonstrated that a pure pairwise end-sequencing strategy would be possible on large targets. The strategy was subsequently adopted by The Institute for Genomic Research (TIGR) to sequence the entire genome of the bacterium Haemophilus influenzae in 1995, [32] and then by Celera Genomics to sequence the entire fruit fly genome in 2000, [33] and subsequently the entire human genome. Applied Biosystems, now called Life Technologies, manufactured the automated capillary sequencers utilized by both Celera Genomics and The Human Genome Project.

Current techniques

While capillary sequencing was the first approach to successfully sequence a nearly full human genome, it is still too expensive and takes too long for commercial purposes. Since 2005, capillary sequencing has been progressively displaced by high-throughput (formerly "next-generation") sequencing technologies such as Illumina dye sequencing, pyrosequencing, and SMRT sequencing. [34] All of these technologies continue to employ the basic shotgun strategy, namely, parallelization and template generation via genome fragmentation.

Other technologies have emerged, including Nanopore technology. Though the sequencing accuracy of Nanopore technology is lower than those above, its read length is on average much longer. [35] This generation of long reads is valuable especially in de novo whole-genome sequencing applications. [36]

Analysis

In principle, full genome sequencing can provide the raw nucleotide sequence of an individual organism's DNA at a single point in time. However, further analysis must be performed to provide the biological or medical meaning of this sequence, such as how this knowledge can be used to help prevent disease. Methods for analyzing sequencing data are being developed and refined.

Because sequencing generates a lot of data (for example, there are approximately six billion base pairs in each human diploid genome), its output is stored electronically and requires a large amount of computing power and storage capacity.

While analysis of WGS data can be slow, it is possible to speed up this step by using dedicated hardware. [37]

Commercialization

Total cost of sequencing a whole human genome as calculated by the NHGRI Historic cost of sequencing a human genome.svg
Total cost of sequencing a whole human genome as calculated by the NHGRI

A number of public and private companies are competing to develop a full genome sequencing platform that is commercially robust for both research and clinical use, [38] including Illumina, [39] Knome, [40] Sequenom, [41] 454 Life Sciences, [42] Pacific Biosciences, [43] Complete Genomics, [44] Helicos Biosciences, [45] GE Global Research (General Electric), Affymetrix, IBM, Intelligent Bio-Systems, [46] Life Technologies, Oxford Nanopore Technologies, [47] and the Beijing Genomics Institute. [48] [49] [50] These companies are heavily financed and backed by venture capitalists, hedge funds, and investment banks. [51] [52]

A commonly-referenced commercial target for sequencing cost until the late 2010s was $1,000  USD, however, the private companies are working to reach a new target of only $100. [53]

Incentive

In October 2006, the X Prize Foundation, working in collaboration with the J. Craig Venter Science Foundation, established the Archon X Prize for Genomics, [54] intending to award $10 million to "the first team that can build a device and use it to sequence 100 human genomes within 10 days or less, with an accuracy of no more than one error in every 1,000,000 bases sequenced, with sequences accurately covering at least 98% of the genome, and at a recurring cost of no more than $1,000 per genome". [55] The Archon X Prize for Genomics was cancelled in 2013, before its official start date. [56] [57]

History

In 2007, Applied Biosystems started selling a new type of sequencer called SOLiD System. [58] The technology allowed users to sequence 60 gigabases per run. [59]

In June 2009, Illumina announced that they were launching their own Personal Full Genome Sequencing Service at a depth of 30× for $48,000 per genome. [60] [61] In August, the founder of Helicos Biosciences, Stephen Quake, stated that using the company's Single Molecule Sequencer he sequenced his own full genome for less than $50,000. [62] In November, Complete Genomics published a peer-reviewed paper in Science demonstrating its ability to sequence a complete human genome for $1,700. [63] [64]

In May 2011, Illumina lowered its Full Genome Sequencing service to $5,000 per human genome, or $4,000 if ordering 50 or more. [65] Helicos Biosciences, Pacific Biosciences, Complete Genomics, Illumina, Sequenom, ION Torrent Systems, Halcyon Molecular, NABsys, IBM, and GE Global appear to all be going head to head in the race to commercialize full genome sequencing. [34] [66]

With sequencing costs declining, a number of companies began claiming that their equipment would soon achieve the $1,000 genome: these companies included Life Technologies in January 2012, [67] Oxford Nanopore Technologies in February 2012, [68] and Illumina in February 2014. [69] [70] In 2015, the NHGRI estimated the cost of obtaining a whole-genome sequence at around $1,500. [71] In 2016, Veritas Genetics began selling whole genome sequencing, including a report as to some of the information in the sequencing for $999. [72] In summer 2019, Veritas Genetics cut the cost for WGS to $599. [73] In 2017, BGI began offering WGS for $600. [74]

However, in 2015, some noted that effective use of whole gene sequencing can cost considerably more than $1000. [75] Also, reportedly there remain parts of the human genome that have not been fully sequenced by 2017. [76] [77]

Comparison with other technologies

DNA microarrays

Full genome sequencing provides information on a genome that is orders of magnitude larger than by DNA arrays, the previous leader in genotyping technology.

For humans, DNA arrays currently provide genotypic information on up to one million genetic variants, [78] [79] [80] while full genome sequencing will provide information on all six billion bases in the human genome, or 3,000 times more data. Because of this, full genome sequencing is considered a disruptive innovation to the DNA array markets as the accuracy of both range from 99.98% to 99.999% (in non-repetitive DNA regions) and their consumables cost of $5000 per 6 billion base pairs is competitive (for some applications) with DNA arrays ($500 per 1 million basepairs). [42]

Applications

Mutation frequencies

Whole genome sequencing has established the mutation frequency for whole human genomes. The mutation frequency in the whole genome between generations for humans (parent to child) is about 70 new mutations per generation. [81] [82] An even lower level of variation was found comparing whole genome sequencing in blood cells for a pair of monozygotic (identical twins) 100-year-old centenarians. [83] Only 8 somatic differences were found, though somatic variation occurring in less than 20% of blood cells would be undetected.

In the specifically protein coding regions of the human genome, it is estimated that there are about 0.35 mutations that would change the protein sequence between parent/child generations (less than one mutated protein per generation). [84]

In cancer, mutation frequencies are much higher, due to genome instability. This frequency can further depend on patient age, exposure to DNA damaging agents (such as UV-irradiation or components of tobacco smoke) and the activity/inactivity of DNA repair mechanisms. [85] Furthermore, mutation frequency can vary between cancer types: in germline cells, mutation rates occur at approximately 0.023 mutations per megabase, but this number is much higher in breast cancer (1.18-1.66 somatic mutations per Mb), in lung cancer (17.7) or in melanomas (≈33). [86] Since the haploid human genome consists of approximately 3,200 megabases, [87] this translates into about 74 mutations (mostly in noncoding regions) in germline DNA per generation, but 3,776-5,312 somatic mutations per haploid genome in breast cancer, 56,640 in lung cancer and 105,600 in melanomas.

The distribution of somatic mutations across the human genome is very uneven, [88] such that the gene-rich, early-replicating regions receive fewer mutations than gene-poor, late-replicating heterochromatin, likely due to differential DNA repair activity. [89] In particular, the histone modification H3K9me3 is associated with high, [90] and H3K36me3 with low mutation frequencies. [91]

Genome-wide association studies

In research, whole-genome sequencing can be used in a Genome-Wide Association Study (GWAS) – a project aiming to determine the genetic variant or variants associated with a disease or some other phenotype. [92]

Diagnostic use

In 2009, Illumina released its first whole genome sequencers that were approved for clinical as opposed to research-only use and doctors at academic medical centers began quietly using them to try to diagnose what was wrong with people whom standard approaches had failed to help. [93] In 2009, a team from Stanford led by Euan Ashley performed clinical interpretation of a full human genome, that of bioengineer Stephen Quake. [94] In 2010, Ashley's team reported whole genome molecular autopsy [95] and in 2011, extended the interpretation framework to a fully sequenced family, the West family, who were the first family to be sequenced on the Illumina platform. [96] The price to sequence a genome at that time was $19,500 USD, which was billed to the patient but usually paid for out of a research grant; one person at that time had applied for reimbursement from their insurance company. [93] For example, one child had needed around 100 surgeries by the time he was three years old, and his doctor turned to whole genome sequencing to determine the problem; it took a team of around 30 people that included 12 bioinformatics experts, three sequencing technicians, five physicians, two genetic counsellors and two ethicists to identify a rare mutation in the XIAP that was causing widespread problems. [93] [97] [98]

Due to recent cost reductions (see above) whole genome sequencing has become a realistic application in DNA diagnostics. In 2013, the 3Gb-TEST consortium obtained funding from the European Union to prepare the health care system for these innovations in DNA diagnostics. [99] [100] Quality assessment schemes, Health technology assessment and guidelines have to be in place. The 3Gb-TEST consortium has identified the analysis and interpretation of sequence data as the most complicated step in the diagnostic process. [101] At the Consortium meeting in Athens in September 2014, the Consortium coined the word genotranslation for this crucial step. This step leads to a so-called genoreport. Guidelines are needed to determine the required content of these reports.[ citation needed ]

Genomes2People (G2P), an initiative of Brigham and Women's Hospital and Harvard Medical School was created in 2011 to examine the integration of genomic sequencing into clinical care of adults and children. [102] G2P's director, Robert C. Green, had previously led the REVEAL study — Risk EValuation and Education for Alzheimer's Disease – a series of clinical trials exploring patient reactions to the knowledge of their genetic risk for Alzheimer's. [103] [104]

In 2018, researchers at Rady Children's Hospital Institute for Genomic Medicine in San Diego determined that rapid whole-genome sequencing (rWGS) could diagnose genetic disorders in time to change acute medical or surgical management (clinical utility) and improve outcomes in acutely ill infants. In a retrospective cohort study of acutely ill inpatient infants in a regional children's hospital from July 2016-March 2017, forty-two families received rWGS for etiologic diagnosis of genetic disorders. The diagnostic sensitivity of rWGS was 43% (eighteen of 42 infants) and 10% (four of 42 infants) for standard genetic tests (P = .0005). The rate of clinical utility of rWGS (31%, thirteen of 42 infants) was significantly greater than for standard genetic tests (2%, one of 42; P = .0015). Eleven (26%) infants with diagnostic rWGS avoided morbidity, one had a 43% reduction in likelihood of mortality, and one started palliative care. In six of the eleven infants, the changes in management reduced inpatient cost by $800,000-$2,000,000. The findings replicated a prior study of the clinical utility of rWGS in acutely ill inpatient infants, and demonstrated improved outcomes, net healthcare savings and consideration as a first tier test in this setting. [105]

A 2018 review of 36 publications found the cost for whole genome sequencing to range from $1,906 USD to $24,810 USD and have a wide variance in diagnostic yield from 17% to 73% depending on patient groups. [106]

Rare variant association study

Whole genome sequencing studies enable the assessment of associations between complex traits and both coding and noncoding rare variants (minor allele frequency (MAF) < 1%) across the genome. Single-variant analyses typically have low power to identify associations with rare variants, and variant set tests have been proposed to jointly test the effects of given sets of multiple rare variants. [107] SNP annotations help to prioritize rare functional variants, and incorporating these annotations can effectively boost the power of genetic association of rare variants analysis of whole genome sequencing studies. [108] Some tools have been specifically developed to provide all-in-one rare variant association analysis for whole-genome sequencing data, including integration of genotype data and their functional annotations, association analysis, result summary and visualization. [109] [110]

Meta-analysis of whole genome sequencing studies provides an attractive solution to the problem of collecting large sample sizes for discovering rare variants associated with complex phenotypes. Some methods have been developed to enable functionally informed rare variant association analysis in biobank-scale cohorts using efficient approaches for summary statistic storage. [111]

Oncology

In this field, whole genome sequencing represents a great set of improvements and challenges to be faced by the scientific community, as it makes it possible to analyze, quantify and characterize circulating tumor DNA (ctDNA) in the bloodstream. This serves as a basis for early cancer diagnosis, treatment selection and relapse monitoring, as well as for determining the mechanisms of resistance, metastasis and phylogenetic patterns in the evolution of cancer. It can also help in the selection of individualized treatments for patients suffering from this pathology and observe how existing drugs are working during the progression of treatment. Deep whole genome sequencing involves a subclonal reconstruction based on ctDNA in plasma that allows for complete epigenomic and genomic profiling, showing the expression of circulating tumor DNA in each case. [112]

Newborn screening

In 2013, Green and a team of researchers launched the BabySeq Project to study the ethical and medical consequences of sequencing a newborn's DNA. [113] [114] As of 2015, whole genome and exome sequencing as a newborn screening tool were deliberated [115] and in 2021, further discussed. [116]

In 2021, the NIH funded BabySeq2, an implementation study that expanded the BabySeq project, enrolling 500 infants from diverse families and track the effects of their genomic sequencing on their pediatric care. [117]

In 2023, the Lancet opined that in the UK "focusing on improving screening by upgrading targeted gene panels might be more sensible in the short term. Whole genome sequencing in the long term deserves thorough examination and universal caution." [118]

Ethical concerns

The introduction of whole genome sequencing may have ethical implications. [119] On one hand, genetic testing can potentially diagnose preventable diseases, both in the individual undergoing genetic testing and in their relatives. [119] On the other hand, genetic testing has potential downsides such as genetic discrimination, loss of anonymity, and psychological impacts such as discovery of non-paternity. [120]

Some ethicists insist that the privacy of individuals undergoing genetic testing must be protected, [119] and is of particular concern when minors undergo genetic testing. [121] Illumina's CEO, Jay Flatley, wrongly claimed in February 2009 that "by 2019 it will have become routine to map infants' genes when they are born". [122] This potential use of genome sequencing is highly controversial, as it runs counter to established ethical norms for predictive genetic testing of asymptomatic minors that have been well established in the fields of medical genetics and genetic counseling. [123] [124] [125] [126] The traditional guidelines for genetic testing have been developed over the course of several decades since it first became possible to test for genetic markers associated with disease, prior to the advent of cost-effective, comprehensive genetic screening.[ citation needed ]

When an individual undergoes whole genome sequencing, they reveal information about not only their own DNA sequences, but also about probable DNA sequences of their close genetic relatives. [119] This information can further reveal useful predictive information about relatives' present and future health risks. [127] Hence, there are important questions about what obligations, if any, are owed to the family members of the individuals who are undergoing genetic testing. In Western/European society, tested individuals are usually encouraged to share important information on any genetic diagnoses with their close relatives, since the importance of the genetic diagnosis for offspring and other close relatives is usually one of the reasons for seeking a genetic testing in the first place. [119] Nevertheless, a major ethical dilemma can develop when the patients refuse to share information on a diagnosis that is made for serious genetic disorder that is highly preventable and where there is a high risk to relatives carrying the same disease mutation. Under such circumstances, the clinician may suspect that the relatives would rather know of the diagnosis and hence the clinician can face a conflict of interest with respect to patient-doctor confidentiality. [119]

Privacy concerns can also arise when whole genome sequencing is used in scientific research studies. Researchers often need to put information on patient's genotypes and phenotypes into public scientific databases, such as locus specific databases. [119] Although only anonymous patient data are submitted to locus specific databases, patients might still be identifiable by their relatives in the case of finding a rare disease or a rare missense mutation. [119] Public discussion around the introduction of advanced forensic techniques (such as advanced familial searching using public DNA ancestry websites and DNA phenotyping approaches) has been limited, disjointed, and unfocused. As forensic genetics and medical genetics converge toward genome sequencing, issues surrounding genetic data become increasingly connected, and additional legal protections may need to be established. [128]

Public human genome sequences

First people with public genome sequences

The first nearly complete human genomes sequenced were two Americans of predominantly Northwestern European ancestry in 2007 (J. Craig Venter at 7.5-fold coverage, [129] [130] [131] and James Watson at 7.4-fold). [132] [133] [134] This was followed in 2008 by sequencing of an anonymous Han Chinese man (at 36-fold), [135] a Yoruban man from Nigeria (at 30-fold), [136] a female clinical geneticist (Marjolein Kriek) from the Netherlands (at 7 to 8-fold), and a female leukemia patient in her mid-50s (at 33 and 14-fold coverage for tumor and normal tissues). [137] Steve Jobs was among the first 20 people to have their whole genome sequenced, reportedly for the cost of $100,000. [138] As of June 2012, there were 69 nearly complete human genomes publicly available. [139] In November 2013, a Spanish family made their personal genomics data publicly available under a Creative Commons public domain license. The work was led by Manuel Corpas and the data obtained by direct-to-consumer genetic testing with 23andMe and the Beijing Genomics Institute. This is believed to be the first such Public Genomics dataset for a whole family. [140]

Databases

According to Science , the major databases of whole genomes are: [141]

BiobankCompleted whole genomesRelease/access information
UK Biobank 500,000Made available through a Web platform in November 2021, it is the largest public dataset of whole genomes. The genomes are linked to anonymized medical information and are made more accessible for biomedical research than prior, less comprehensive datasets. 300,000 more genomes were released in early 2023. [141] [142] [143]
Trans-Omics for Precision Medicine161,000 National Institutes of Health (NIH) requires project-specific consent
Million Veteran Program125,000Non–Veterans Affairs researchers get access in 2022
Genomics England's 100,000 Genomes 120,000Researchers must join collaboration
All of Us 90,000NIH expects to release by early 2022

Genomic coverage

In terms of genomic coverage and accuracy, whole genome sequencing can broadly be classified into either of the following: [144]

Producing a truly high-quality finished sequence by this definition is very expensive. Thus, most human "whole genome sequencing" results are draft sequences (sometimes above and sometimes below the accuracy defined above). [144]

See also

Sequenced genomes

Related Research Articles

<span class="mw-page-title-main">Human genome</span> Complete set of nucleic acid sequences for humans

The human genome is a complete set of nucleic acid sequences for humans, encoded as DNA within the 23 chromosome pairs in cell nuclei and in a small DNA molecule found within individual mitochondria. These are usually treated separately as the nuclear genome and the mitochondrial genome. Human genomes include both protein-coding DNA sequences and various types of DNA that does not encode proteins. The latter is a diverse category that includes DNA coding for non-translated RNA, such as that for ribosomal RNA, transfer RNA, ribozymes, small nuclear RNAs, and several types of regulatory RNAs. It also includes promoters and their associated gene-regulatory elements, DNA playing structural and replicatory roles, such as scaffolding regions, telomeres, centromeres, and origins of replication, plus large numbers of transposable elements, inserted viral DNA, non-functional pseudogenes and simple, highly repetitive sequences. Introns make up a large percentage of non-coding DNA. Some of this non-coding DNA is non-functional junk DNA, such as pseudogenes, but there is no firm consensus on the total amount of junk DNA.

A microsatellite is a tract of repetitive DNA in which certain DNA motifs are repeated, typically 5–50 times. Microsatellites occur at thousands of locations within an organism's genome. They have a higher mutation rate than other areas of DNA leading to high genetic diversity. Microsatellites are often referred to as short tandem repeats (STRs) by forensic geneticists and in genetic genealogy, or as simple sequence repeats (SSRs) by plant geneticists.

<span class="mw-page-title-main">Genomics</span> Discipline in genetics

Genomics is an interdisciplinary field of molecular biology focusing on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism's complete set of DNA, including all of its genes as well as its hierarchical, three-dimensional structural configuration. In contrast to genetics, which refers to the study of individual genes and their roles in inheritance, genomics aims at the collective characterization and quantification of all of an organism's genes, their interrelations and influence on the organism. Genes may direct the production of proteins with the assistance of enzymes and messenger molecules. In turn, proteins make up body structures such as organs and tissues as well as control chemical reactions and carry signals between cells. Genomics also involves the sequencing and analysis of genomes through uses of high throughput DNA sequencing and bioinformatics to assemble and analyze the function and structure of entire genomes. Advances in genomics have triggered a revolution in discovery-based research and systems biology to facilitate understanding of even the most complex biological systems such as the brain.

<span class="mw-page-title-main">DNA sequencer</span> A scientific instrument used to automate the DNA sequencing process

A DNA sequencer is a scientific instrument used to automate the DNA sequencing process. Given a sample of DNA, a DNA sequencer is used to determine the order of the four bases: G (guanine), C (cytosine), A (adenine) and T (thymine). This is then reported as a text string, called a read. Some DNA sequencers can be also considered optical instruments as they analyze light signals originating from fluorochromes attached to nucleotides.

<span class="mw-page-title-main">Molecular genetics</span> Scientific study of genes at the molecular level

Molecular genetics is a branch of biology that addresses how differences in the structures or expression of DNA molecules manifests as variation among organisms. Molecular genetics often applies an "investigative approach" to determine the structure and/or function of genes in an organism's genome using genetic screens. 

<span class="mw-page-title-main">Single-nucleotide polymorphism</span> Single nucleotide in genomic DNA at which different sequence alternatives exist

In genetics and bioinformatics, a single-nucleotide polymorphism is a germline substitution of a single nucleotide at a specific position in the genome. Although certain definitions require the substitution to be present in a sufficiently large fraction of the population, many publications do not apply such a frequency threshold.

<span class="mw-page-title-main">Functional genomics</span> Field of molecular biology

Functional genomics is a field of molecular biology that attempts to describe gene functions and interactions. Functional genomics make use of the vast data generated by genomic and transcriptomic projects. Functional genomics focuses on the dynamic aspects such as gene transcription, translation, regulation of gene expression and protein–protein interactions, as opposed to the static aspects of the genomic information such as DNA sequence or structures. A key characteristic of functional genomics studies is their genome-wide approach to these questions, generally involving high-throughput methods rather than a more traditional "candidate-gene" approach.

<span class="mw-page-title-main">DNA sequencing</span> Process of determining the nucleic acid sequence

DNA sequencing is the process of determining the nucleic acid sequence – the order of nucleotides in DNA. It includes any method or technology that is used to determine the order of the four bases: adenine, guanine, cytosine, and thymine. The advent of rapid DNA sequencing methods has greatly accelerated biological and medical research and discovery.

Personal genomics or consumer genetics is the branch of genomics concerned with the sequencing, analysis and interpretation of the genome of an individual. The genotyping stage employs different techniques, including single-nucleotide polymorphism (SNP) analysis chips, or partial or full genome sequencing. Once the genotypes are known, the individual's variations can be compared with the published literature to determine likelihood of trait expression, ancestry inference and disease risk.

<span class="mw-page-title-main">1000 Genomes Project</span> International research effort on genetic variation

The 1000 Genomes Project (1KGP), taken place from January 2008 to 2015, was an international research effort to establish the most detailed catalogue of human genetic variation at the time. Scientists planned to sequence the genomes of at least one thousand anonymous healthy participants from a number of different ethnic groups within the following three years, using advancements in newly developed technologies. In 2010, the project finished its pilot phase, which was described in detail in a publication in the journal Nature. In 2012, the sequencing of 1092 genomes was announced in a Nature publication. In 2015, two papers in Nature reported results and the completion of the project and opportunities for future research.

The exome is composed of all of the exons within the genome, the sequences which, when transcribed, remain within the mature RNA after introns are removed by RNA splicing. This includes untranslated regions of messenger RNA (mRNA), and coding regions. Exome sequencing has proven to be an efficient method of determining the genetic basis of more than two dozen Mendelian or single gene disorders.

Complete Genomics is a life sciences company that has developed and commercialized a DNA sequencing platform for human genome sequencing and analysis. This solution combines the company's proprietary human genome sequencing technology with its informatics and data management software to provide finished variant reports and assemblies at Complete Genomics’ commercial genome center in Mountain View, California.

Cancer genome sequencing is the whole genome sequencing of a single, homogeneous or heterogeneous group of cancer cells. It is a biochemical laboratory method for the characterization and identification of the DNA or RNA sequences of cancer cell(s).

<span class="mw-page-title-main">Exome sequencing</span> Sequencing of all the exons of a genome

Exome sequencing, also known as whole exome sequencing (WES), is a genomic technique for sequencing all of the protein-coding regions of genes in a genome. It consists of two steps: the first step is to select only the subset of DNA that encodes proteins. These regions are known as exons—humans have about 180,000 exons, constituting about 1% of the human genome, or approximately 30 million base pairs. The second step is to sequence the exonic DNA using any high-throughput DNA sequencing technology.

<span class="mw-page-title-main">$1,000 genome</span> Era of predictive and personalized medicine

The $1,000 genome refers to an era of predictive and personalized medicine during which the cost of fully sequencing an individual's genome (WGS) is roughly one thousand USD. It is also the title of a book by British science writer and founding editor of Nature Genetics, Kevin Davies. By late 2015, the cost to generate a high-quality "draft" whole human genome sequence was just below $1,500.

Single-cell sequencing examines the nucleic acid sequence information from individual cells with optimized next-generation sequencing technologies, providing a higher resolution of cellular differences and a better understanding of the function of an individual cell in the context of its microenvironment. For example, in cancer, sequencing the DNA of individual cells can give information about mutations carried by small populations of cells. In development, sequencing the RNAs expressed by individual cells can give insight into the existence and behavior of different cell types. In microbial systems, a population of the same species can appear genetically clonal. Still, single-cell sequencing of RNA or epigenetic modifications can reveal cell-to-cell variability that may help populations rapidly adapt to survive in changing environments.

<span class="mw-page-title-main">Variant of uncertain significance</span>

A variant of uncertainsignificance (VUS) is a genetic variant that has been identified through genetic testing but whose significance to the function or health of an organism is not known. Two related terms are "gene of uncertain significance" (GUS), which refers to a gene that has been identified through genome sequencing but whose connection to a human disease has not been established, and "insignificant mutation", referring to a gene variant that has no impact on the health or function of an organism. The term "variant' is favored in clinical practice over "mutation" because it can be used to describe an allele more precisely. When the variant has no impact on health, it is called a "benign variant". When it is associated with a disease, it is called a "pathogenic variant". A "pharmacogenomic variant" has an effect only when an individual takes a particular drug and therefore is neither benign nor pathogenic.

A plant genome assembly represents the complete genomic sequence of a plant species, which is assembled into chromosomes and other organelles by using DNA fragments that are obtained from different types of sequencing technology.

Personalized onco-genomics (POG) is the field of oncology and genomics that is focused on using whole genome analysis to make personalized clinical treatment decisions. The program was devised at British Columbia's BC Cancer Agency and is currently being led by Marco Marra and Janessa Laskin. Genome instability has been identified as one of the underlying hallmarks of cancer. The genetic diversity of cancer cells promotes multiple other cancer hallmark functions that help them survive in their microenvironment and eventually metastasise. The pronounced genomic heterogeneity of tumours has led researchers to develop an approach that assesses each individual's cancer to identify targeted therapies that can halt cancer growth. Identification of these "drivers" and corresponding medications used to possibly halt these pathways are important in cancer treatment.

Personalized genomics is the human genetics-derived study of analyzing and interpreting individualized genetic information by genome sequencing to identify genetic variations compared to the library of known sequences. International genetics communities have spared no effort from the past and have gradually cooperated to prosecute research projects to determine DNA sequences of the human genome using DNA sequencing techniques. The methods that are the most commonly used are whole exome sequencing and whole genome sequencing. Both approaches are used to identify genetic variations. Genome sequencing became more cost-effective over time, and made it applicable in the medical field, allowing scientists to understand which genes are attributed to specific diseases.

References

  1. ↑ Alberts, Bruce; Johnson, Alexander; Lewis, Julian; Raff, Martin; Roberts, Keith; Walter, Peter (2008). "Chapter 8". Molecular biology of the cell (5th ed.). New York: Garland Science. p. 550. ISBN   978-0-8153-4106-2.
  2. ↑ "Definition of whole-genome sequencing – NCI Dictionary of Cancer Terms". National Cancer Institute. 2012-07-20. Retrieved 2018-10-13.
  3. ↑ Gilissen (July 2014). "Genome sequencing identifies major causes of severe intellectual disability". Nature. 511 (7509): 344–7. Bibcode:2014Natur.511..344G. doi:10.1038/nature13394. hdl: 2066/138095 . PMID   24896178. S2CID   205238886.
  4. ↑ Nones, K; Waddell, N; Wayte, N; Patch, AM; Bailey, P; Newell, F; Holmes, O; Fink, JL; Quinn, MC; Tang, YH; Lampe, G; Quek, K; Loffler, KA; Manning, S; Idrisoglu, S; Miller, D; Xu, Q; Waddell, N; Wilson, PJ; Bruxner, TJ; Christ, AN; Harliwong, I; Nourse, C; Nourbakhsh, E; Anderson, M; Kazakoff, S; Leonard, C; Wood, S; Simpson, PT; Reid, LE; Krause, L; Hussey, DJ; Watson, DI; Lord, RV; Nancarrow, D; Phillips, WA; Gotley, D; Smithers, BM; Whiteman, DC; Hayward, NK; Campbell, PJ; Pearson, JV; Grimmond, SM; Barbour, AP (29 October 2014). "Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis". Nature Communications. 5: 5224. Bibcode:2014NatCo...5.5224N. doi:10.1038/ncomms6224. PMC   4596003 . PMID   25351503.
  5. ↑ van El, CG; Cornel, MC; Borry, P; Hastings, RJ; Fellmann, F; Hodgson, SV; Howard, HC; Cambon-Thomsen, A; Knoppers, BM; Meijers-Heijboer, H; Scheffer, H; Tranebjaerg, L; Dondorp, W; de Wert, GM (June 2013). "Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics". European Journal of Human Genetics. 21 (Suppl 1): S1–5. doi:10.1038/ejhg.2013.46. PMC   3660957 . PMID   23819146.
  6. ↑ Mooney, Sean (Sep 2014). "Progress towards the integration of pharmacogenomics in practice". Human Genetics. 134 (5): 459–65. doi:10.1007/s00439-014-1484-7. PMC   4362928 . PMID   25238897.
  7. ↑ Kijk magazine, 01 January 2009
  8. ↑ Marx, Vivien (11 September 2013). "Next-generation sequencing: The genome jigsaw". Nature. 501 (7466): 263–268. Bibcode:2013Natur.501..263M. doi: 10.1038/501261a . PMID   24025842.
  9. ↑ al.], Bruce Alberts ... [et (2008). Molecular biology of the cell (5th ed.). New York: Garland Science. p. 551. ISBN   978-0-8153-4106-2.
  10. ↑ Fiers, W.; Contreras, R.; Duerinck, F.; Haegeman, G.; Iserentant, D.; Merregaert, J.; Min Jou, W.; Molemans, F.; Raeymaekers, A.; Van den Berghe, A.; Volckaert, G.; Ysebaert, M. (8 April 1976). "Complete nucleotide sequence of bacteriophage MS2 RNA: primary and secondary structure of the replicase gene". Nature. 260 (5551): 500–507. Bibcode:1976Natur.260..500F. doi:10.1038/260500a0. PMID   1264203. S2CID   4289674.
  11. ↑ Oliver, S. G.; van der Aart, Q. J. M.; Agostoni-Carbone, M. L.; et al. (May 1992). "The complete DNA sequence of yeast chromosome III". Nature. 357 (6373): 38–46. Bibcode:1992Natur.357...38O. doi:10.1038/357038a0. PMID   1574125. S2CID   4271784.
  12. 1 2 3 Fleischmann, R.; Adams, M.; White, O; Clayton, R.; Kirkness, E.; Kerlavage, A.; Bult, C.; Tomb, J.; Dougherty, B.; Merrick, J.; al., e. (28 July 1995). "Whole-genome random sequencing and assembly of Haemophilus influenzae Rd". Science. 269 (5223): 496–512. Bibcode:1995Sci...269..496F. doi:10.1126/science.7542800. PMID   7542800.
  13. ↑ Eddy, Sean R. (November 2012). "The C-value paradox, junk DNA and ENCODE". Current Biology. 22 (21): R898–R899. Bibcode:2012CBio...22.R898E. doi: 10.1016/j.cub.2012.10.002 . PMID   23137679.
  14. ↑ Pellicer, Jaume; FAY, Michael F.; Leitch, Ilia J. (15 September 2010). "The largest eukaryotic genome of them all?". Botanical Journal of the Linnean Society. 164 (1): 10–15. doi:10.1111/j.1095-8339.2010.01072.x.
  15. ↑ Human Genome Sequencing Consortium, International (21 October 2004). "Finishing the euchromatic sequence of the human genome". Nature. 431 (7011): 931–945. Bibcode:2004Natur.431..931H. doi: 10.1038/nature03001 . PMID   15496913.
  16. ↑ Goffeau, A.; Barrell, B. G.; Bussey, H.; Davis, R. W.; Dujon, B.; Feldmann, H.; Galibert, F.; Hoheisel, J. D.; Jacq, C.; Johnston, M.; Louis, E. J.; Mewes, H. W.; Murakami, Y.; Philippsen, P.; Tettelin, H.; Oliver, S. G. (25 October 1996). "Life with 6000 Genes". Science. 274 (5287): 546–567. Bibcode:1996Sci...274..546G. doi:10.1126/science.274.5287.546. PMID   8849441. S2CID   16763139. Archived (PDF) from the original on 7 March 2016.
  17. ↑ The C. elegans Sequencing Consortium (11 December 1998). "Genome Sequence of the Nematode C. elegans: A Platform for Investigating Biology". Science. 282 (5396): 2012–2018. Bibcode:1998Sci...282.2012.. doi:10.1126/science.282.5396.2012. PMID   9851916.
  18. ↑ Alberts, Bruce (2008). Molecular Biology of the Cell (5th ed.). New York: Garland Science. p. 552. ISBN   978-0-8153-4106-2.
  19. ↑ Dunham, I. (December 1999). "The DNA sequence of human chromosome 22". Nature. 402 (6761): 489–495. Bibcode:1999Natur.402..489D. doi: 10.1038/990031 . PMID   10591208.
  20. ↑ Adams MD; Celniker SE; Holt RA; et al. (2000-03-24). "The Genome Sequence of Drosophila melanogaster". Science. 287 (5461): 2185–2195. Bibcode:2000Sci...287.2185.. CiteSeerX   10.1.1.549.8639 . doi:10.1126/science.287.5461.2185. PMID   10731132.
  21. ↑ The Arabidopsis Genome Initiative (2000-12-14). "Analysis of the genome sequence of the flowering plant Arabidopsis thaliana". Nature. 408 (6814): 796–815. Bibcode:2000Natur.408..796T. doi: 10.1038/35048692 . PMID   11130711.
  22. ↑ Venter JC; Adams MD; Myers EW; et al. (2001-02-16). "The Sequence of the Human Genome". Science. 291 (5507): 1304–1351. Bibcode:2001Sci...291.1304V. doi:10.1126/science.1058040. PMID   11181995.
  23. ↑ Waterston RH; Lindblad-Toh K; Birney E; et al. (2002-10-31). "Initial sequencing and comparative analysis of the mouse genome". Nature. 420 (6915): 520–562. Bibcode:2002Natur.420..520W. doi: 10.1038/nature01262 . PMID   12466850.
  24. ↑ International Human Genome Sequencing Consortium (2004-09-07). "Finishing the euchromatic sequence of the human genome". Nature. 431 (7011): 931–945. Bibcode:2004Natur.431..931H. doi: 10.1038/nature03001 . PMID   15496913.
  25. ↑ Braslavsky, Ido; et al. (2003). "Sequence information can be obtained from single DNA molecules". Proc Natl Acad Sci USA. 100 (7): 3960–3984. Bibcode:2003PNAS..100.3960B. doi: 10.1073/pnas.0230489100 . PMC   153030 . PMID   12651960.
  26. ↑ Heger, Monica (October 2, 2013). "Single-cell Sequencing Makes Strides in the Clinic with Cancer and PGD First Applications" . Clinical Sequencing News.
  27. ↑ Yurkiewicz, I. R.; Korf, B. R.; Lehmann, L. S. (2014). "Prenatal whole-genome sequencing--is the quest to know a fetus's future ethical?". New England Journal of Medicine. 370 (3): 195–7. doi:10.1056/NEJMp1215536. PMID   24428465.
  28. ↑ Staden R (June 1979). "A strategy of DNA sequencing employing computer programs". Nucleic Acids Res. 6 (7): 2601–10. doi:10.1093/nar/6.7.2601. PMC   327874 . PMID   461197.
  29. ↑ Edwards, A; Caskey, T (1991). "Closure strategies for random DNA sequencing". Methods: A Companion to Methods in Enzymology. 3 (1): 41–47. doi:10.1016/S1046-2023(05)80162-8.
  30. ↑ Edwards A; Voss H; Rice P; Civitello A; Stegemann J; Schwager C; Zimmermann J; Erfle H; Caskey CT; Ansorge W (April 1990). "Automated DNA sequencing of the human HPRT locus". Genomics. 6 (4): 593–608. doi:10.1016/0888-7543(90)90493-E. PMID   2341149.
  31. ↑ Roach JC; Boysen C; Wang K; Hood L (March 1995). "Pairwise end sequencing: a unified approach to genomic mapping and sequencing". Genomics. 26 (2): 345–53. doi:10.1016/0888-7543(95)80219-C. PMID   7601461.
  32. ↑ Fleischmann RD; Adams MD; White O; Clayton RA; Kirkness EF; Kerlavage AR; Bult CJ; Tomb JF; Dougherty BA; Merrick JM; McKenney; Sutton; Fitzhugh; Fields; Gocyne; Scott; Shirley; Liu; Glodek; Kelley; Weidman; Phillips; Spriggs; Hedblom; Cotton; Utterback; Hanna; Nguyen; Saudek; et al. (July 1995). "Whole-genome random sequencing and assembly of Haemophilus influenzae Rd". Science. 269 (5223): 496–512. Bibcode:1995Sci...269..496F. doi:10.1126/science.7542800. PMID   7542800.
  33. ↑ Adams, MD; et al. (2000). "The genome sequence of Drosophila melanogaster". Science. 287 (5461): 2185–95. Bibcode:2000Sci...287.2185.. CiteSeerX   10.1.1.549.8639 . doi:10.1126/science.287.5461.2185. PMID   10731132.
  34. 1 2 Mukhopadhyay R (February 2009). "DNA sequencers: the next generation". Anal. Chem. 81 (5): 1736–40. doi:10.1021/ac802712u. PMID   19193124.
  35. ↑ Sevim, Volkan; Lee, Juna; Egan, Robert; Clum, Alicia; Hundley, Hope; Lee, Janey; Everroad, R. Craig; Detweiler, Angela M.; Bebout, Brad M.; Pett-Ridge, Jennifer; Göker, Markus; Murray, Alison E.; Lindemann, Stephen R.; Klenk, Hans-Peter; O'Malley, Ronan (2019-11-26). "Shotgun metagenome data of a defined mock community using Oxford Nanopore, PacBio and Illumina technologies". Scientific Data. 6 (1): 285. Bibcode:2019NatSD...6..285S. doi:10.1038/s41597-019-0287-z. ISSN   2052-4463. PMC   6879543 . PMID   31772173.
  36. ↑ Wang, Yunhao; Zhao, Yue; Bollas, Audrey; Wang, Yuru; Au, Kin Fai (November 2021). "Nanopore sequencing technology, bioinformatics and applications". Nature Biotechnology. 39 (11): 1348–1365. doi:10.1038/s41587-021-01108-x. ISSN   1546-1696. PMC   8988251 . PMID   34750572.
  37. ↑ Strickland, Eliza (2015-10-14). "New Genetic Technologies Diagnose Critically Ill Infants Within 26 Hours – IEEE Spectrum". IEEE . Archived from the original on 2015-11-16. Retrieved 2016-11-11.
  38. ↑ "Article : Race to Cut Whole Genome Sequencing Costs Genetic Engineering & Biotechnology News — Biotechnology from Bench to Business". Genengnews.com. Archived from the original on 2006-10-17. Retrieved 2009-02-23.
  39. ↑ "Whole Genome Sequencing Costs Continue to Drop". Eyeondna.com. Archived from the original on 2009-03-25. Retrieved 2009-02-23.
  40. ↑ Harmon, Katherine (2010-06-28). "Genome Sequencing for the Rest of Us". Scientific American. Archived from the original on 2011-03-19. Retrieved 2010-08-13.
  41. ↑ San Diego/Orange County Technology News. "Sequenom to Develop Third-Generation Nanopore-Based Single Molecule Sequencing Technology". Freshnews.com. Archived from the original on 2008-12-05. Retrieved 2009-02-24.
  42. 1 2 "Article : Whole Genome Sequencing in 24 Hours Genetic Engineering & Biotechnology News — Biotechnology from Bench to Business". Genengnews.com. Archived from the original on 2006-10-17. Retrieved 2009-02-23.
  43. ↑ "Pacific Bio lifts the veil on its high-speed genome-sequencing effort". VentureBeat. 2008-02-10. Archived from the original on 2009-02-20. Retrieved 2009-02-23.
  44. ↑ "Bio-IT World". Bio-IT World. 2008-10-06. Archived from the original on 2009-02-17. Retrieved 2009-02-23.
  45. ↑ "With New Machine, Helicos Brings Personal Genome Sequencing A Step Closer". Xconomy. 2008-04-22. Archived from the original on 2011-01-02. Retrieved 2011-01-28.
  46. ↑ "Whole genome sequencing costs continue to fall: $300 million in 2003, $1 million 2007, $60,000 now, $5000 by year end". Nextbigfuture.com. 2008-03-25. Archived from the original on 2010-12-20. Retrieved 2011-01-28.
  47. ↑ "Han Cao's nanofluidic chip could cut DNA sequencing costs dramatically". Technology Review. Archived from the original on 2011-03-29.
  48. ↑ Julia Karow (26 October 2015). "BGI Launches Desktop Sequencer in China; Plans to Register Platform With CFDA". GenomeWeb. Retrieved 2 December 2018.
  49. ↑ "BGI Launches New Desktop Sequencer in China, Registers Larger Version With CFDA". 360Dx. GenomeWeb. 11 November 2016. Retrieved 2 December 2018.
  50. ↑ Monica Heger (26 October 2018). "BGI Launches New Sequencer as Customers Report Data From Earlier Instruments". GenomeWeb. Retrieved 2 December 2018.
  51. ↑ John Carroll (2008-07-14). "Pacific Biosciences gains $100M for sequencing tech". FierceBiotech. Archived from the original on 2009-05-01. Retrieved 2009-02-23.
  52. ↑ Sibley, Lisa (2009-02-08). "Complete Genomics brings radical reduction in cost". Silicon Valley / San Jose Business Journal. Retrieved 2009-02-23.
  53. ↑ Sarah Neville (5 March 2018). "Cheaper DNA sequencing unlocks secrets of rare diseases". Financial Times . Retrieved 2 December 2018.
  54. ↑ Carlson, Rob (2007-01-02). "A Few Thoughts on Rapid Genome Sequencing and The Archon Prize — synthesis". Synthesis.cc. Archived from the original on 2009-08-08. Retrieved 2009-02-23.
  55. ↑ "PRIZE Overview: Archon X PRIZE for Genomics".
  56. ↑ Diamandis, Peter. "Outpaced by Innovation: Canceling an XPRIZE". Huffington Post. Archived from the original on 2013-08-25.
  57. ↑ Aldhous, Peter. "X Prize for genomes cancelled before it begins". Archived from the original on 2016-09-21.
  58. ↑ "SOLiD System — a next-gen DNA sequencing platform announced". Gizmag.com. 2007-10-27. Archived from the original on 2008-07-19. Retrieved 2009-02-24.
  59. ↑ "The $1000 Genome: Coming Soon?". Dddmag.com. 2010-04-01. Archived from the original on 2011-04-15. Retrieved 2011-01-28.
  60. ↑ "Individual genome sequencing — Illumina, Inc". Everygenome.com. Archived from the original on 2011-10-19. Retrieved 2011-01-28.
  61. ↑ "Illumina launches personal genome sequencing service for $48,000 : Genetic Future". Scienceblogs.com. Archived from the original on June 16, 2009. Retrieved 2011-01-28.
  62. ↑ Wade, Nicholas (2009-08-11). "Cost of Decoding a Genome Is Lowered". The New York Times. Archived from the original on 2013-05-21. Retrieved 2010-05-03.
  63. ↑ "Technology Index". ABC News. Archived from the original on 15 May 2016. Retrieved 29 April 2018.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  64. ↑ Drmanac R, Sparks AB, Callow MJ, et al. (2010). "Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays". Science. 327 (5961): 78–81. Bibcode:2010Sci...327...78D. doi: 10.1126/science.1181498 . PMID   19892942. S2CID   17309571.
  65. ↑ "Illumina Announces $5,000 Genome Pricing – Bio-IT World". Archived from the original on 2011-05-17.
  66. ↑ "NHGRI Awards More than $50M for Low-Cost DNA Sequencing Tech Development". Genome Web. 2009. Archived from the original on 2011-07-03.
  67. ↑ "Life Technologies Introduces the Benchtop Ion Proton™ Sequencer; Designed to Decode a Human Genome in One Day for $1,000" (press release). Archived from the original on December 23, 2012. Retrieved August 30, 2012.
  68. ↑ ANDREW POLLACK (2012-02-17). "Oxford Nanopore Unveils Tiny DNA Sequencing Device – The New York Times". The New York Times. Archived from the original on 2013-01-07. Retrieved 2016-11-11.
  69. ↑ "Illumina Sequencer Enables $1,000 Genome". News: Genomics & Proteomics. Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. 15 February 2014. p. 18.
  70. ↑ Check Hayden, Erika (15 January 2014). "Is the $1,000 genome for real?". Nature: nature.2014.14530. doi:10.1038/nature.2014.14530. S2CID   211730238.
  71. ↑ "The Cost of Sequencing a Human Genome". www.genome.gov. Archived from the original on 2016-11-25.
  72. ↑ "With $999 Whole-Genome Sequencing Service, Veritas Embarks on Goal to Democratize DNA Information". 6 March 2016.
  73. ↑ Andrews, Joe (2019-07-01). "23andMe competitor Veritas Genetics slashes price of whole genome sequencing 40% to $600". CNBC. Retrieved 2019-09-02.
  74. ↑ Megan Molteni (18 May 2017). "A Chinese Genome Giant Sets Its Sights on the Ultimate Sequencer". Wired . Retrieved 2 December 2018.
  75. ↑ Phillips, K. A; Pletcher, M. J; Ladabaum, U (2015). "Is the "$1000 Genome" Really $1000? Understanding the Full Benefits and Costs of Genomic Sequencing". Technology and Health Care. 23 (3): 373–379. doi:10.3233/THC-150900. PMC   4527943 . PMID   25669213.
  76. ↑ "Blog: True Size of a Human Genome | Veritas Genetics". 28 July 2017.
  77. ↑ "Psst, the human genome was never completely sequenced". statnews.com. 2017-06-20.
  78. ↑ "Genomics Core". Gladstone.ucsf.edu. Archived from the original on June 30, 2010. Retrieved 2009-02-23.
  79. ↑ Nishida N; Koike A; Tajima A; Ogasawara Y; Ishibashi Y; Uehara Y; Inoue I; Tokunaga K (2008). "Evaluating the performance of Affymetrix SNP Array 6.0 platform with 400 Japanese individuals". BMC Genomics. 9 (1): 431. doi: 10.1186/1471-2164-9-431 . PMC   2566316 . PMID   18803882.
  80. ↑ Petrone, Justin (16 January 2007). "Illumina, DeCode Build 1M SNP Chip; Q2 Launch to Coincide with Release of Affy's 6.0 SNP Array | BioArray News | Arrays". GenomeWeb. Archived from the original on 2011-07-16. Retrieved 2009-02-23.
  81. ↑ Roach JC; Glusman G; Smit AF; et al. (April 2010). "Analysis of genetic inheritance in a family quartet by whole-genome sequencing". Science. 328 (5978): 636–9. Bibcode:2010Sci...328..636R. doi:10.1126/science.1186802. PMC   3037280 . PMID   20220176.
  82. ↑ Campbell CD; Chong JX; Malig M; et al. (November 2012). "Estimating the human mutation rate using autozygosity in a founder population". Nat. Genet. 44 (11): 1277–81. doi:10.1038/ng.2418. PMC   3483378 . PMID   23001126.
  83. ↑ Ye K; Beekman M; Lameijer EW; Zhang Y; Moed MH; van den Akker EB; Deelen J; Houwing-Duistermaat JJ; Kremer D; Anvar SY; Laros JF; Jones D; Raine K; Blackburne B; Potluri S; Long Q; Guryev V; van der Breggen R; Westendorp RG; 't Hoen PA; den Dunnen J; van Ommen GJ; Willemsen G; Pitts SJ; Cox DR; Ning Z; Boomsma DI; Slagboom PE (December 2013). "Aging as accelerated accumulation of somatic variants: whole-genome sequencing of centenarian and middle-aged monozygotic twin pairs". Twin Res Hum Genet. 16 (6): 1026–32. doi: 10.1017/thg.2013.73 . PMID   24182360.
  84. ↑ Keightley PD (February 2012). "Rates and fitness consequences of new mutations in humans". Genetics. 190 (2): 295–304. doi:10.1534/genetics.111.134668. PMC   3276617 . PMID   22345605.
  85. ↑ Mustjoki S, Young NS. Somatic Mutations in "Benign" Disease. N Engl J Med. 2021 May 27;384(21):2039-2052. doi: 10.1056/NEJMra2101920. PMID: 34042390.
  86. ↑ Tuna M; Amos CI (November 2013). "Genomic sequencing in cancer". Cancer Lett. 340 (2): 161–70. doi:10.1016/j.canlet.2012.11.004. PMC   3622788 . PMID   23178448.
  87. ↑ Moran, Laurence A. (24 March 2011). "Sandwalk: How Big Is the Human Genome?". sandwalk.blogspot.com. Archived from the original on 1 December 2017. Retrieved 29 April 2018.
  88. ↑ Hodgkinson, Alan; Chen, Ying; Eyre-Walker, Adam (January 2012). "The large-scale distribution of somatic mutations in cancer genomes". Human Mutation. 33 (1): 136–143. doi:10.1002/humu.21616. PMID   21953857. S2CID   19353116.
  89. ↑ Supek, Fran; Lehner, Ben (May 2015). "Differential DNA mismatch repair underlies mutation rate variation across the human genome". Nature. 521 (7550): 81–84. Bibcode:2015Natur.521...81S. doi:10.1038/nature14173. PMC   4425546 . PMID   25707793.
  90. ↑ Schuster-Böckler, Benjamin; Lehner, Ben (August 2012). "Chromatin organization is a major influence on regional mutation rates in human cancer cells". Nature. 488 (7412): 504–507. Bibcode:2012Natur.488..504S. doi:10.1038/nature11273. PMID   22820252. S2CID   205229634.
  91. ↑ Supek, Fran; Lehner, Ben (July 2017). "Clustered Mutation Signatures Reveal that Error-Prone DNA Repair Targets Mutations to Active Genes". Cell. 170 (3): 534–547.e23. doi: 10.1016/j.cell.2017.07.003 . hdl: 10230/35343 . PMID   28753428.
  92. ↑ Yano, K; Yamamoto, E; Aya, K; Takeuchi, H; Lo, PC; Hu, L; Yamasaki, M; Yoshida, S; Kitano, H; Hirano, K; Matsuoka, M (August 2016). "Genome-wide association study using whole-genome sequencing rapidly identifies new genes influencing agronomic traits in rice". Nature Genetics. 48 (8): 927–34. doi:10.1038/ng.3596. PMID   27322545. S2CID   22427006.
  93. 1 2 3 Borrell, Brendan (14 September 2010). "US clinics quietly embrace whole-genome sequencing". Nature: news.2010.465. doi:10.1038/news.2010.465.
  94. ↑ Ashley, EA; Butte, AJ; Wheeler, MT; Chen, R; Klein, TE; Dewey, FE; Dudley, JT; Ormond, KE; Pavlovic, A; Morgan, AA; Pushkarev, D; Neff, NF; Hudgins, L; Gong, L; Hodges, LM; Berlin, DS; Thorn, CF; Sangkuhl, K; Hebert, JM; Woon, M; Sagreiya, H; Whaley, R; Knowles, JW; Chou, MF; Thakuria, JV; Rosenbaum, AM; Zaranek, AW; Church, GM; Greely, HT; Quake, SR; Altman, RB (1 May 2010). "Clinical assessment incorporating a personal genome". Lancet. 375 (9725): 1525–35. doi:10.1016/S0140-6736(10)60452-7. PMC   2937184 . PMID   20435227.
  95. ↑ Dewey, Frederick E.; Wheeler, Matthew T.; Cordero, Sergio; Perez, Marco V.; Pavlovic, Aleks; Pushkarev, Dmitry; Freeman, James V.; Quake, Steve R.; Ashley, Euan A. (April 2011). "Molecular Autopsy for Sudden Cardiac Death Using Whole Genome Sequencing". Journal of the American College of Cardiology. 57 (14): E1159. doi:10.1016/S0735-1097(11)61159-5.
  96. ↑ Dewey, Frederick E.; Chen, Rong; Cordero, Sergio P.; Ormond, Kelly E.; Caleshu, Colleen; Karczewski, Konrad J.; Whirl-Carrillo, Michelle; Wheeler, Matthew T.; Dudley, Joel T.; Byrnes, Jake K.; Cornejo, Omar E.; Knowles, Joshua W.; Woon, Mark; Sangkuhl, Katrin; Gong, Li; Thorn, Caroline F.; Hebert, Joan M.; Capriotti, Emidio; David, Sean P.; Pavlovic, Aleksandra; West, Anne; Thakuria, Joseph V.; Ball, Madeleine P.; Zaranek, Alexander W.; Rehm, Heidi L.; Church, George M.; West, John S.; Bustamante, Carlos D.; Snyder, Michael; Altman, Russ B.; Klein, Teri E.; Butte, Atul J.; Ashley, Euan A. (15 September 2011). "Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence". PLOS Genetics. 7 (9): e1002280. doi: 10.1371/journal.pgen.1002280 . PMC   3174201 . PMID   21935354.
  97. ↑ "One In A Billion: A boy's life, a medical mystery". Jsonline.com. Archived from the original on 2013-10-05. Retrieved 2016-11-11.
  98. ↑ Mayer AN, Dimmock DP, Arca MJ, et al. (March 2011). "A timely arrival for genomic medicine". Genet. Med. 13 (3): 195–6. doi: 10.1097/GIM.0b013e3182095089 . PMID   21169843. S2CID   10802499.
  99. ↑ "Introducing diagnostic applications of '3Gb-testing' in human genetics". Archived from the original on 2014-11-10.
  100. ↑ Boccia S, Mc Kee M, Adany R, Boffetta P, Burton H, Cambon-Thomsen A, Cornel MC, Gray M, Jani A, Knoppers BM, Khoury MJ, Meslin EM, Van Duijn CM, Villari P, Zimmern R, Cesario A, Puggina A, Colotto M, Ricciardi W (August 2014). "Beyond public health genomics: proposals from an international working group". Eur J Public Health. 24 (6): 877–879. doi:10.1093/eurpub/cku142. PMC   4245010 . PMID   25168910.
  101. ↑ "RD-Connect News 18 July 2014". Rd-connect.eu. Archived from the original on 10 October 2016. Retrieved 2016-11-11.
  102. ↑ "Genomes2People: A Roadmap for Genomic Medicine". www.frontlinegenomics.com. Archived from the original on 14 February 2017. Retrieved 29 April 2018.
  103. ↑ "The Risk Evaluation and Education for Alzheimer's Disease (REVEAL) Study – HBHE Genetics Research Group". hbhegenetics.sph.umich.edu. Archived from the original on 29 September 2017. Retrieved 29 April 2018.
  104. ↑ "Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II – Full Text View – ClinicalTrials.gov". clinicaltrials.gov. 22 July 2009. Archived from the original on 14 February 2017. Retrieved 29 April 2018.
  105. ↑ Farnaes, Lauge; Hildreth, Amber; Sweeney, Nathaly M.; Clark, Michelle M.; Chowdhury, Shimul; Nahas, Shareef; Cakici, Julie A.; Benson, Wendy; Kaplan, Robert H.; Kronick, Richard; Bainbridge, Matthew N.; Friedman, Jennifer; Gold, Jeffrey J.; Ding, Yan; Veeraraghavan, Narayanan; Dimmock, David; Kingsmore, Stephen F. (December 2018). "Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization". npj Genomic Medicine. 3 (1): 10. doi:10.1038/s41525-018-0049-4. PMC   5884823 . PMID   29644095.
  106. ↑ Schwarze, K; Buchanan, J; Taylor, Jc; Wordsworth, S (May 2018). "Are whole Exome and whole Genome Sequencing Approaches Cost-Effective? A Systematic Review of the Literature". Value in Health. 21: S100. doi: 10.1016/j.jval.2018.04.677 .
  107. ↑ Lee, Seunggeung; Abecasis, Gonçalo R.; Boehnke, Michael; Lin, Xihong (July 2014). "Rare-Variant Association Analysis: Study Designs and Statistical Tests". The American Journal of Human Genetics. 95 (1): 5–23. doi:10.1016/j.ajhg.2014.06.009. PMC   4085641 . PMID   24995866.
  108. ↑ Li, Xihao; Li, Zilin; Zhou, Hufeng; et al. (September 2020). "Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale". Nature Genetics. 52 (9): 969–983. doi:10.1038/s41588-020-0676-4. PMC   7483769 . PMID   32839606.
  109. ↑ Li, Zilin; Li, Xihao; Zhou, Hufeng; et al. (December 2022). "A framework for detecting noncoding rare-variant associations of large-scale whole-genome sequencing studies". Nature Methods. 19 (12): 1599–1611. doi:10.1038/s41592-022-01640-x. PMC   10008172 . PMID   36303018. S2CID   243873361.
  110. ↑ "STAARpipeline: an all-in-one rare-variant tool for biobank-scale whole-genome sequencing data". Nature Methods. 19 (12): 1532–1533. December 2022. doi:10.1038/s41592-022-01641-w. PMID   36316564. S2CID   253246835.
  111. ↑ Li, Xihao; Quick, Corbin; Zhou, Hufeng; Gaynor, Sheila M.; Liu, Yaowu; Chen, Han; Selvaraj, Margaret Sunitha; Sun, Ryan; Dey, Rounak; Arnett, Donna K. (January 2023). "Powerful, scalable and resource-efficient meta-analysis of rare variant associations in large whole genome sequencing studies". Nature Genetics. 55 (1): 154–164. doi:10.1038/s41588-022-01225-6. PMC   10084891 . PMID   36564505. S2CID   255084231.
  112. ↑ Herberts, Cameron; Annala, Matti; Sipola, Joonatan; Ng, Sarah W. S.; Chen, Xinyi E.; Nurminen, Anssi; Korhonen, Olga V.; Munzur, Aslı D.; Beja, Kevin; Schönlau, Elena; Bernales, Cecily Q.; Ritch, Elie; Bacon, Jack V. W.; Lack, Nathan A.; Nykter, Matti (August 2022). "Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer". Nature. 608 (7921): 199–208. Bibcode:2022Natur.608..199H. doi:10.1038/s41586-022-04975-9. ISSN   1476-4687. PMID   35859180. S2CID   250730778.
  113. ↑ "Boston Researchers To Sequence Newborn Babies' DNA". wbur.org. 2013-09-05.
  114. ↑ Holm, Ingrid A.; Agrawal, Pankaj B.; Ceyhan-Birsoy, Ozge; Christensen, Kurt D.; Fayer, Shawn; Frankel, Leslie A.; Genetti, Casie A.; Krier, Joel B.; Lamay, Rebecca C.; Levy, Harvey L.; McGuire, Amy L.; Parad, Richard B.; Park, Peter J.; Pereira, Stacey; Rehm, Heidi L.; Schwartz, Talia S.; Waisbren, Susan E.; Yu, Timothy W.; Green, Robert C.; Beggs, Alan H. (2018-07-09). "The BabySeq project: implementing genomic sequencing in newborns". BMC Pediatrics. 18 (1): 225. doi: 10.1186/s12887-018-1200-1 . PMC   6038274 . PMID   29986673.
  115. ↑ Howard, Heidi Carmen; Knoppers, Bartha Maria; Cornel, Martina C.; Wright Clayton, Ellen; Sénécal, Karine; Borry, Pascal (2015-01-28). "Whole-genome sequencing in newborn screening? A statement on the continued importance of targeted approaches in newborn screening programmes". European Journal of Human Genetics. 23 (12): 1593–1600. doi:10.1038/ejhg.2014.289. ISSN   1476-5438. PMC   4795188 . PMID   25626707.
  116. ↑ Woerner, Audrey C.; Gallagher, Renata C.; Vockley, Jerry; Adhikari, Aashish N. (2021-07-19). "The Use of Whole Genome and Exome Sequencing for Newborn Screening: Challenges and Opportunities for Population Health". Frontiers in Pediatrics. 9: 663752. doi: 10.3389/fped.2021.663752 . ISSN   2296-2360. PMC   8326411 . PMID   34350142.
  117. ↑ Tarini, Beth A. (2021-08-23). "The Effect of BabySeq on Pediatric and Genomic Research—More Than Baby Steps". JAMA Pediatrics. 175 (11): 1107–1108. doi:10.1001/jamapediatrics.2021.2826. PMID   34424259. S2CID   237267536.
  118. ↑ The Lancet (2023-07-22). "Genomic newborn screening: current concerns and challenges". The Lancet. 402 (10398): 265. doi:10.1016/s0140-6736(23)01513-1. ISSN   0140-6736. PMID   37481265.
  119. 1 2 3 4 5 6 7 8 Sijmons, R.H.; Van Langen, I.M (2011). "A clinical perspective on ethical issues in genetic testing". Accountability in Research: Policies and Quality Assurance. 18 (3): 148–162. Bibcode:2013ARPQ...20..143D. doi:10.1080/08989621.2011.575033. PMID   21574071. S2CID   24935558.
  120. ↑ Ayday E; De Cristofaro E; Hubaux JP; Tsudik G (2015). "The Chills and Thrills of Whole Genome Sequencing". arXiv: 1306.1264 [cs.CR].
  121. ↑ Borry, Pascal; Evers-Kiebooms, Gerry; Cornel, Martha C.; Clarke, Angus; Dierickx, Kris (2009). "Genetic testing in asymptomatic minors Background considerations towards ESHG Recommendations". European Journal of Human Genetics. 17 (6): 711–9. doi:10.1038/ejhg.2009.25. PMC   2947094 . PMID   19277061.
  122. ↑ Henderson, Mark (2009-02-09). "Genetic mapping of babies by 2019 will transform preventive medicine". London: Times Online. Archived from the original on 2009-05-11. Retrieved 2009-02-23.
  123. ↑ McCabe LL; McCabe ER (June 2001). "Postgenomic medicine. Presymptomatic testing for prediction and prevention". Clin Perinatol. 28 (2): 425–34. doi:10.1016/S0095-5108(05)70094-4. PMID   11499063.
  124. ↑ Nelson RM; Botkjin JR; Kodish ED; et al. (June 2001). "Ethical issues with genetic testing in pediatrics". Pediatrics. 107 (6): 1451–5. doi:10.1542/peds.107.6.1451. PMID   11389275. S2CID   9993840.
  125. ↑ Borry P; Fryns JP; Schotsmans P; Dierickx K (February 2006). "Carrier testing in minors: a systematic review of guidelines and position papers". Eur. J. Hum. Genet. 14 (2): 133–8. doi: 10.1038/sj.ejhg.5201509 . PMID   16267502.
  126. ↑ Borry P; Stultiens L; Nys H; Cassiman JJ; Dierickx K (November 2006). "Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers". Clin. Genet. 70 (5): 374–81. doi:10.1111/j.1399-0004.2006.00692.x. PMID   17026616. S2CID   7066285.
  127. ↑ McGuire, Amy, L; Caulfield, Timothy (2008). "Science and Society: Research ethics and the challenge of whole-genome sequencing". Nature Reviews Genetics. 9 (2): 152–156. doi:10.1038/nrg2302. PMC   2225443 . PMID   18087293.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  128. ↑ Curtis, Caitlin; Hereward, James; Mangelsdorf, Marie; Hussey, Karen; Devereux, John (18 December 2018). "Protecting trust in medical genetics in the new era of forensics". Genetics in Medicine. 21 (7): 1483–1485. doi:10.1038/s41436-018-0396-7. PMC   6752261 . PMID   30559376.
  129. ↑ Wade, Nicholas (September 4, 2007). "In the Genome Race, the Sequel Is Personal". The New York Times . Archived from the original on April 11, 2009. Retrieved February 22, 2009.
  130. ↑ Ledford, Heidi (2007). "Access : All about Craig: the first 'full' genome sequence". Nature. 449 (7158): 6–7. Bibcode:2007Natur.449....6L. doi: 10.1038/449006a . PMID   17805257.
  131. ↑ Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, Lin Y, MacDonald JR, Pang AW, Shago M, Stockwell TB, Tsiamouri A, Bafna V, Bansal V, Kravitz SA, Busam DA, Beeson KY, McIntosh TC, Remington KA, Abril JF, Gill J, Borman J, Rogers YH, Frazier ME, Scherer SW, Strausberg RL, Venter JC (September 2007). "The diploid genome sequence of an individual human". PLOS Biol. 5 (10): e254. doi: 10.1371/journal.pbio.0050254 . PMC   1964779 . PMID   17803354.
  132. ↑ Wade, Wade (June 1, 2007). "DNA pioneer Watson gets own genome map". International Herald Tribune. Archived from the original on September 27, 2008. Retrieved February 22, 2009.
  133. ↑ Wade, Nicholas (May 31, 2007). "Genome of DNA Pioneer Is Deciphered". The New York Times . Archived from the original on June 20, 2011. Retrieved February 21, 2009.
  134. ↑ Wheeler DA; Srinivasan M; Egholm M; Shen Y; Chen L; McGuire A; He W; Chen YJ; Makhijani V; Roth GT; Gomes X; Tartaro K; Niazi F; Turcotte CL; Irzyk GP; Lupski JR; Chinault C; Song XZ; Liu Y; Yuan Y; Nazareth L; Qin X; Muzny DM; Margulies M; Weinstock GM; Gibbs RA; Rothberg JM (2008). "The complete genome of an individual by massively parallel DNA sequencing". Nature. 452 (7189): 872–6. Bibcode:2008Natur.452..872W. doi: 10.1038/nature06884 . PMID   18421352.
  135. ↑ Wang J; Wang, Wei; Li, Ruiqiang; Li, Yingrui; Tian, Geng; Goodman, Laurie; Fan, Wei; Zhang, Junqing; Li, Jun; Zhang, Juanbin, Juanbin; Guo, Yiran, Yiran; Feng, Binxiao, Binxiao; Li, Heng, Heng; Lu, Yao, Yao; Fang, Xiaodong, Xiaodong; Liang, Huiqing, Huiqing; Du, Zhenglin, Zhenglin; Li, Dong, Dong; Zhao, Yiqing, Yiqing; Hu, Yujie, Yujie; Yang, Zhenzhen, Zhenzhen; Zheng, Hancheng, Hancheng; Hellmann, Ines, Ines; Inouye, Michael, Michael; Pool, John, John; Yi, Xin, Xin; Zhao, Jing, Jing; Duan, Jinjie, Jinjie; Zhou, Yan, Yan; et al. (2008). "The diploid genome sequence of an Asian individual". Nature. 456 (7218): 60–65. Bibcode:2008Natur.456...60W. doi:10.1038/nature07484. PMC   2716080 . PMID   18987735.
  136. ↑ Bentley DR; Balasubramanian S; et al. (2008). "Accurate whole human genome sequencing using reversible terminator chemistry". Nature. 456 (7218): 53–9. Bibcode:2008Natur.456...53B. doi:10.1038/nature07517. PMC   2581791 . PMID   18987734.
  137. ↑ Ley TJ; Mardis ER; Ding L; Fulton B; McLellan MD; Chen K; Dooling D; Dunford-Shore BH; McGrath S; Hickenbotham M; Cook L; Abbott R; Larson DE; Koboldt DC; Pohl C; Smith S; Hawkins A; Abbott S; Locke D; Hillier LW; Miner T; Fulton L; Magrini V; Wylie T; Glasscock J; Conyers J; Sander N; Shi X; Osborne JR; et al. (2008). "DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome". Nature. 456 (7218): 66–72. Bibcode:2008Natur.456...66L. doi:10.1038/nature07485. PMC   2603574 . PMID   18987736.
  138. ↑ Lohr, Steve (2011-10-20). "New Book Details Jobs's Fight Against Cancer". The New York Times. Archived from the original on 2017-09-28.
  139. ↑ "Complete Human Genome Sequencing Datasets to its Public Genomic Repository". Archived from the original on June 10, 2012.
  140. ↑ Corpas M, Cariaso M, Coletta A, Weiss D, Harrison AP, Moran F, Yang H (November 12, 2013). "A Complete Public Domain Family Genomics Dataset". bioRxiv   10.1101/000216 .
  141. 1 2 "200,000 whole genomes made available for biomedical studies by U.K. effort". www.science.org. Retrieved 11 December 2021.
  142. ↑ "Whole Genome Sequencing data on 200,000 UK Biobank participants available now". www.ukbiobank.ac.uk. 17 November 2021. Retrieved 11 December 2021.
  143. ↑ Callaway, Ewen (2023-11-30). "World's biggest set of human genome sequences opens to scientists". Nature. 624 (7990): 16–17. doi:10.1038/d41586-023-03763-3. PMID   38036674.
  144. 1 2 Kris A. Wetterstrand, M.S. "The Cost of Sequencing a Human Genome". National Human Genome Research Institute . Last updated: November 1, 2021
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.